The Supply Projects effort is broken down into 7 WPs, here you can find a brief summary of their participants and goals.
WP1 – Project management and coordination
Lead Beneficary: 1. EBA
Start Month: 1
End Month: 18
Objectives
This WP will safeguard the effective execution of the proposed project and the delivery of quality results within time and budget. It will ensure appropriate liaison with the European Commission and with and between the external Advisory Board (quality assurance, risk and ethical management), and the internal Project Management Board. It will coordinate the work and progress in all WPs, ensure communication flows among partners and manage common consortium activities. It will oversee all administrative, financial and contractual aspects of the project.
Participants:
1.EBA
2.SQ
7.IPFA
8.EFS
11.IBTS
13.TKA
WP2 – Donor recruitment and retention best practices
Lead Beneficary: 4. UH
Start Month: 1
End Month: 15
Objectives
To provide evidence-based recommendations and implementation tools towards best practices regarding (unpaid) plasma donor recruitment and retention.
Participants:
1.EBS
4.UH
5.DRK-BSD
8.EFS
9.CNS
13.RKA
WP3 – Plasma collection and processing best practices
Lead Beneficary: 2. SQ
Start Month: 1
End Month: 16
Objectives
To develop a set of recommendations that will support increased and improved plasma collection programmes by BEs throughout Europe and will ultimately strengthen the resilience of plasma collection during crisis. To achieve this the following sub-objectives are defined:
- identify the most suitable approach for BE’s to start or increase their collection programmes and assist BE’s with decision making
- establish efficient ways to enable plasma donation and manufacture
- establish ways to reduce the waste of plasma and lost opportunities for plasmapheresis
- describe the cost model for plasma collection
- determine recommendations for a plasma price and cost modelling based on plasma quality
Participants:
1.EBA
2.SQ
3.RKV
5.DRK-BSD
7.IPFA
8.EFS
12.AUH
13.TKA
WP4 – National and EU infrastructures / policy/legal framework for plasma collection and PDMPs supply
Lead Beneficary: 9. CNS
Start Month: 1
End Month: 16
Objectives
The main objective of WP4 is to formulate recommendations for the development of a proposal of common EU policies (or also legal framework) aimed to support national and EU efforts to achieve a higher degree of strategic independence from non-EU sources in the collection of plasma and its fractionation in PDMPs. It will investigate the presence and the effectiveness of different national legislation/policies aimed at promoting strategic independence in the public sector for PDMPs coming from national plasma. It will emphasize the framework capable to mitigate the effects of the decrease in plasma availability (and consequently of PDMPs on the market) reported by pharmaceutical companies following the Covid-19 pandemic and, in general, in any crisis of plasma supply from outside Europe. To achieve this goal the following sub-objectives are defined:
- Gain clear insight into the current European national policies/legal frameworks for a) the strategic independence in collection of plasma for fractionation b) the management of Call: [EU4H-2021-PJ-05] — [Increase resilience, ensure continuity of supply and access to safe and high quality therapies, in particular in times of crisis] 42 PDMPs coming from national plasma collection.
- Assess the national demand for PDMPs, including pharmaceutical expenditure.
- Assess the national needs of plasma for fractionation.
- Identify and compare the different tendering models for the choice of the fractionator.
- Gain a clear understanding and description of the state-of-the art of plasma economics which can be useful and educational for BEs in their interaction with the fractionators.
Participants:
1.EBS
7.IPFA
8.EFS
9.CNS
10.CVT
14.IPST IP
WP5 – Plasma donor protection best practices
Lead Beneficary: 12. AUH
Start Month: 1
End Month: 14
Objectives
To facilitate evidence-based plasma donor protection practices.
Participants:
1.EBA
2.SQ
3.RKV
5.DRK-BSD
7.IPFA
8.EFS
12.AUH
WP6 – Demand: Clinical programme on appropriate/prioritised use of PDMPs
Lead Beneficary: 6. EHA
Start Month: 1
End Month: 14
Objectives
To deliver a set of recommendations on the appropriate use of PDMPs at baseline and on its prioritisation in times of crisis.
Although a number of PDMPs are manufactured from plasma, emphasis will primarily be on polyvalent immunoglobulin (intravenous – IVIG, intramuscular – IMIG and subtananeous – SubcuIG) because, as currently the most important PDMP, this product, use of which is increasing by about 7% yearly, determines the volume of plasma needed for European strategic independence.
Participants:
1.EBS
5.DRK-BSD
6.EHA
7.IPFA
9.CNS
WP7 – Dissemination and communication
Lead Beneficary: 1. EBA
Start Month: 1
End Month: 18
Objectives
The main objective is to design and implement a 2-step dissemination, exploitation and communication strategyto raise awareness about the SUPPLY project and to disseminate its main results, while building up a long-lasting ‘recommendations’ identity. The WP will target the relevant audiences and stakeholders, including policy makers.
The final users will be: Blood Establishments, medical and healthcare centres (e.g. hospital managers), Competent Authorities, donor associations, healthcare providers, scientific societies and academics as well as the general public to ensure maximum dissemination of the delivered recommendations across the EU. The dissemination and communication strategy and tools will be developed mainly by EBA with support from consortium members, all partners will contribute to publications and dialogue with parallel project initiatives.
Participants:
1.EBA
2.SQ
4.UH
5.DRK-BSD
6.EHA
7.IPFA
8.EFS
9.CNS
10.CVT
11.IBTS
12.AUH
14.IPST IP